Jefferies raises Revvity price target to $125, maintains hold
On Monday, Jefferies updated its outlook on Revvity Inc (NYSE: RVTY), increasing the price target to $125 from $115, while keeping a Hold rating on the stock. The adjustment follows Revvity’s second-quarter performance, which showcased robust revenues and earnings per share (EPS), exceeding expectations. The company also indicated an upward revision for its full-year EPS forecast.
The analyst noted that despite facing challenges such as the market situation in China, issues within applied genomics, and instrument sales, there is a cautiously optimistic view on the biopharmaceutical sector and expectations of growth in China’s prenatal screening and applied genomics by the fourth quarter. This sentiment echoes a notion that the worst may be over for the biopharma industry.
Revvity’s capital deployment strategy has been highlighted, showing a preference for share repurchases over mergers and acquisitions, citing high valuations in the M&A space. In the second quarter, Revvity repurchased $20 million worth of shares, with $330 million remaining in its buyback authorization.
Furthermore, the company’s free cash flow (FCF) has shown improvement, reportedly reaching approximately $300 million year-to-date, which represents more than 100% of its adjusted net income. This financial position underscores Revvity’s ability to generate cash well above its net earnings, providing a solid foundation for future investments or shareholder returns.
In other recent news, Revvity Inc reported second-quarter 2024 revenue of $692 million, slightly surpassing expectations, and an adjusted earnings per share (EPS) of $1.22, exceeding the consensus forecast. The company has updated its full-year 2024 guidance, projecting revenues to be between $2.77 billion and $2.79 billion, marking an increase of $0.10 from previous estimates.
Revvity’s diagnostics segment and margin performance were highlights, although these positives were somewhat counterbalanced by weaker results in the Life Sciences division. Following the release of the second quarter results, Stifel anticipates that Revvity’s shares might experience limited movement, possibly seeing a slight increase due to the improved earnings guidance.
InvestingPro Insights
Revvity Inc’s (NYSE: RVTY) recent performance has caught the eye of analysts and investors alike. With Jefferies setting a new price target, it’s worth looking at some key metrics and insights from InvestingPro to understand the company’s current financial landscape. The company boasts an impressive market capitalization of $15.48 billion and a high P/E ratio of 101.74, which adjusts to 42.46 on a last twelve months basis as of Q1 2024. This indicates that investors have high expectations for the company’s future earnings growth.
InvestingPro Tips reveal that management’s aggressive share buybacks and a high shareholder yield are notable strategies that Revvity is employing, demonstrating confidence in the company’s value and commitment to returning value to shareholders. Additionally, the expectation of net income growth this year adds to the positive outlook. Moreover, Revvity has maintained dividend payments for an impressive 54 consecutive years, which might be appealing for income-focused investors. With 6 additional InvestingPro Tips available, those interested in a deeper dive can find more expert analysis and guidance.
For readers looking to explore these insights further, InvestingPro offers a detailed analysis with additional tips. Use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, providing more in-depth information that could help in making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
